опасности алискирена и диабет

[Melnichenko]

The FDA warned Friday against combining the blood pressure medication aliskiren (Tekturna) with ACE inhibitors and angiotensin receptor blockers (ARBS) in patients with diabetes or renal impairment.

The warning, which will be accompanied by a label change, is based on results from the terminated ALTITUDE study, which found an increased risk of adverse events in high-risk patients taking the direct renin inhibitor as an add-on to other anti-hypertensive medications.

Diabetic patients who mix the drugs are at risk of renal impairment, hypotension, and hyperkalemia, the FDA said in a statement.

Patients with moderate to severe renal impairment (glomerular filtration rate <60 mL/min) should also avoid the potentially lethal combinations.

Medications that contain aliskiren include:

Amturnide (aliskiren hemifumarate, amlodipine besylate, and hydrochlorothiazide)
Tekturna (aliskiren hemifumarate)
Tekturna HCT (aliskiren hemifumarate and hydrochlorothiazide)
Tekamlo (aliskiren hemifumarate and amlodipine besylate)
Valturna (aliskiren hemifumarate and valsartan). Valturna will no longer be marketed after July 2012

[Samitin]

И те же ограничения от EMA: [Ссылки доступны только зарегистрированным пользователям ].